Recent News

• 11.24.2025 - Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
• 11.24.2025 - Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
• 11.14.2025 - Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
• 11.06.2025 - Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
• 11.06.2025 - Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
• 10.28.2025 - Cidara Therapeutics to Participate in November Investor Conferences

Recent Filings

• 11.17.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SC TO-C Written communication relating to an issuer or third party
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - EX-99.1 EX-99.1
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SC14D9C Written communication relating to third party tender offer